Beacon Biomedical announced the commercial release of the BeScreened Colorectal Cancer test. BeScreened improves access and affordability to CRC screening as a blood-draw instead of a fecal collection.
I am anchor
Cancer test provides affordable early detection
Beacon Biomedical announced the commercial release of the BeScreened Colorectal Cancer test.
BeScreened improves access and affordability to CRC screening as a blood-draw instead of a fecal collection.
The company is led by Jason McGrath, a colon cancer survivor.
Colorectal Cancer is the second deadliest and second most costly cancer in the United States. More than 150,000 American are newly diagnosed with CRC every year and greater than 50,000 Americans die from the disease annually.
Despite these alarming statistics, of the 131 million men and women in the US who are eligible each year for CRC screening, a staggering 45 million do not participate. BeScreened is a laboratory developed test that was developed for average risk men and women aged 45 and older who prefer blood-based testing to other screening modalities such as fecal-based tests and colonoscopy.
McGrath is an Iraq veteran who was diagnosed with stage 3 colon cancer at 41 years old. While undergoing 18 months of chemotherapy and three surgeries, he acquired Beacon Biomedical in 2022.
Beacon Biomedical developed the BeScreened-CRC test to drive improved compliance and early detection—which leads to survival rates of 90%, compared to just 14% if detected later.
"Too many lives are lost every year to colorectal cancer. The real tragedy is the majority of these deaths are preventable as they can be directly attributed to non-compliance with existing screening methods,” says Don Weber, Founder & CEO of Beacon Biomedical. “As a simple, easy to adopt, and highly accurate blood-based test for CRC screening, BeScreened was developed to address this very problem.”
BeScreened presents the trifecta in CRC screening. Individuals can purchase a test that is the preferred blood-based modality, is among the most accurate in the industry, and priced far more affordable than alternative screening options. The test is 94.6% accurate and cash priced at $349.
Tests are available now, across the country. Information can be found at www.BeScreened.com. Video, interviews, and images available immediately upon request.